NasdaqCM - Nasdaq Real Time Price USD

Oncolytics Biotech Inc. (ONCY)

0.5833

+0.0167

+(2.95%)

At close: April 24 at 4:00:00 PM EDT

0.5880

+0.00

+(0.81%)

After hours: April 24 at 4:54:31 PM EDT

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options.

PR Newswire 20 hours ago

ONCY
+2.95%
Oncolytics Up 1.5% in U.S. Pre-market as Funds Pelareorep's Ongoing Clinical Development

Oncolytics Biotech (ONC.TO, ONCY), a clinical-stage company specializing in immunotherapy for oncolo

PREMIUM
MT Newswires 13 days ago

ONCY
+2.95%
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. The SPA allows Oncolytics to be judicious and p

CNW Group 14 days ago

ONCY
+2.95%
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright.

PR Newswire 14 days ago

ONCY
+2.95%
Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

Oncolytics Biotech Inc (ONCY) reports significant advancements in cancer research despite increased net loss and leadership uncertainties.

GuruFocus.com last month

ONCY
+2.95%
Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

Oncolytics Biotech (ONC.TO, ONCY) on Friday said its fourth-quarter net loss doubled as the company

PREMIUM
MT Newswires last month

ONCY
+2.95%
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. All dollar amounts are expressed i

PR Newswire last month

ONCY
+2.95%
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

ONCY
+2.95%
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024.

PR Newswire last month

ONCY
+2.95%
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new

CNW Group 2 months ago

ONCY
+2.95%
Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

Oncolytics Biotech (ONC.TO), down 4.6% in U.S. pre-market trading, on Tuesday said it has obtained s

PREMIUM
MT Newswires 2 months ago

ONCY
+2.95%
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new

PR Newswire 2 months ago

ONCY
+2.95%
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Marke

PR Newswire 2 months ago

ONCY
+2.95%
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President and Chief Executive Officer, will not return following a medical leave of absence and ongoing health concerns. After much thought and consideration, Dr. Coffey reached a decision that in the best interest of his family and Oncolytics Biotech Inc., he would officially step down as CEO and Director of the company.

CNW Group 2 months ago

ONCY
+2.95%
Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such times, penny stocks—often smaller or newer companies—can offer intriguing opportunities for those looking beyond established names. While the term "penny stocks" may seem outdated, these investments continue to hold potential for growth and value, especially when backed by strong financials.

Simply Wall St. 2 months ago

RMRDF

CONXF

ONCY
+2.95%
Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

ONCY
+2.95%
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

Initial efficacy outcomes from cohort 5 are anticipated in the second half of this year.

Clinical Trials Arena 3 months ago

ONCY
+2.95%
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) pa

PR Newswire 3 months ago

ONCY
+2.95%
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

ONCY
+2.95%
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is providing a recap of the major accomplishments from 2024 and a preview of the milestones that are expected over the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across our clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities.

PR Newswire 3 months ago

ONCY
+2.95%

Performance Overview

Return	ONCY	S&P/TSX Composite index (^GSPTSE)
YTD	-37.28%	+0.43%
1-Year	-44.97%	+13.05%
3-Year	-56.79%	+16.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oncolytics Biotech Inc. (ONCY)

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Up 1.5% in U.S. Pre-market as Funds Pelareorep's Ongoing Clinical Development

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Performance Overview